The document discusses making a business case for a PARP inhibitor drug in the ovarian cancer market. It provides information from various data sources on competitor drugs and clinical trials, the size of the ovarian cancer market, sales forecasts for Lynparza and other PARP inhibitors, and deal values that phase 1 oncology drugs and PARP inhibitors have achieved when licensed.
Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD, prepared useful Practice Aids pertaining to PARP inhibitors for this CME/CNE activity titled, "Advances in Precision Care in Solid Tumor Oncology: Defining the Role of PARP Inhibitors." For the full presentation, monograph, complete CME/CNE information, and to apply for credit, please visit us at http://bit.ly/2MWKmUN. CME/CNE credit will be available until November 7, 2020.
First immunotherapy for early stage triple-negative breast cancerDoriaFang
On July 27, Merck (MSD) announced that the FDA approved its blockbuster PD-1 antibody therapy Keytruda in combination with chemotherapy, as a neoadjuvant therapy before surgery, then continued as single agent as an adjuvant therapy after surgery, to treat high-risk early-stage triple-negative breast cancer (TNBC) patients.
TNBC has had the bearings of a protagonist for Immuno oncology in breast ever since the discovery of its molecular subtypes. Recent FDA approvals of Immunotherapies and some of the ASCO 2020 highlights hold the promise of an more optimistic outlook for drug development for this cancer. Finally I close with some thoughts on ensuring patient safety and centricity in the changed circumstances of the post Covid times.
An Overview of Pancreatic Cancer - Creative BiolabsCreative-Biolabs
Pancreatic cancer is one of the malignant tumors with strong invasiveness, high degree of deterioration and low surgical resection rate in the digestive system. Optimizing early diagnosis and developing targeted therapy of pancreatic cancer are the key to improving the survival rate of patients. The slide named an overview of pancreatic cancer is created by Creative Biolabs who provides high-quality antibody production with advanced research tools, professional technical support, and rapid global delivery. In the slide, we will give you a comprehensive introduction to pancreatic cancer and its signaling pathways, diagnostics markers and targeted therapies, as well as Creative Biolabs’ antibody-related products and services. It is believed that you can fully understand how important it is to optimize early diagnosis and develop targeted drugs.
Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD, prepared useful Practice Aids pertaining to PARP inhibitors for this CME/CNE activity titled, "Advances in Precision Care in Solid Tumor Oncology: Defining the Role of PARP Inhibitors." For the full presentation, monograph, complete CME/CNE information, and to apply for credit, please visit us at http://bit.ly/2MWKmUN. CME/CNE credit will be available until November 7, 2020.
First immunotherapy for early stage triple-negative breast cancerDoriaFang
On July 27, Merck (MSD) announced that the FDA approved its blockbuster PD-1 antibody therapy Keytruda in combination with chemotherapy, as a neoadjuvant therapy before surgery, then continued as single agent as an adjuvant therapy after surgery, to treat high-risk early-stage triple-negative breast cancer (TNBC) patients.
TNBC has had the bearings of a protagonist for Immuno oncology in breast ever since the discovery of its molecular subtypes. Recent FDA approvals of Immunotherapies and some of the ASCO 2020 highlights hold the promise of an more optimistic outlook for drug development for this cancer. Finally I close with some thoughts on ensuring patient safety and centricity in the changed circumstances of the post Covid times.
An Overview of Pancreatic Cancer - Creative BiolabsCreative-Biolabs
Pancreatic cancer is one of the malignant tumors with strong invasiveness, high degree of deterioration and low surgical resection rate in the digestive system. Optimizing early diagnosis and developing targeted therapy of pancreatic cancer are the key to improving the survival rate of patients. The slide named an overview of pancreatic cancer is created by Creative Biolabs who provides high-quality antibody production with advanced research tools, professional technical support, and rapid global delivery. In the slide, we will give you a comprehensive introduction to pancreatic cancer and its signaling pathways, diagnostics markers and targeted therapies, as well as Creative Biolabs’ antibody-related products and services. It is believed that you can fully understand how important it is to optimize early diagnosis and develop targeted drugs.
How can immunotherapy be used to treat metastatic breast cancer? Ian Krop, MD, PhD, discusses the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 and hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Tratamiento inicial de pacientes posmenopáusicas con cáncer de mama HR+/her2-...Mauricio Lema
Versión 2 (definitiva): Presentado en la Clínica VIDA en 11.11.2016, por invitación de Jairo Estrada. Versión corregida (se corrigen errores en 3 diapositivas de la versión anterior).
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Pharma Intelligence
In conjunction with a Key Opinion Leader, Dr. Peter Lee MD Chair, Department of Immuno-Oncology at City of Hope Comprehensive Cancer Center, CA, several Informa analysts discuss the major developments of the conference and key take-aways via a Webinar.
Watch our recording of Biomedtracker's Robert Jeng, Ph,D., Citeline's Allison Bruce, Scrip's Mary Jo Laffler, and Datamonitor Healthcare's Zachary McLellan as they download and debrief following the always-exciting ASCO weekend.
View and listen to the full webinar here https://www.youtube.com/watch?v=7yMsCb3R5X8
Your fast-pass to the news, insights, and storylines you need to know.
Watch the full webinar here http://ow.ly/4mOGmk
Hosted by Master of Ceremonies Ian Lloyd, senior director of Pharmaprojects and data integration, this webinar spotlights the blockbuster trends and rising stars of global R&D 2016 as seen in this year’s Annual Review.
During this presentation, Ian Lloyd & Scrip Managing Editor, Alex Shimmings cover:
>> Year-on-year growth
>> Clinical phases trends
>> Top companies and the shape of the industry
>> Mergers and acquisitions
>> Trending therapies, diseases, drug types and delivery routes
>> Mechanisms and drug targets
This webinar is the essential pharma R&D trend and forecast overview you need to be positioned for success in 2016.
Watch the full webinar here http://ow.ly/4mOGmk
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Tahoe eLab
This presentation has been peer-reviewed for fair and balanced evidence-based medicine.
Status of FDA devices used for the material being presented: NA/Non-Clinical
Status of off-label use of devices, drugs or other materials that constitute the subject of this presentation: Discuss off-label use of chemotherapy drugs for different cancers.
This is a briefing on the PD-1 and PD-L1 targeted agents. This briefing provides a summary of the agents in clinical development for the treatment of cancer. The briefing specifically focusses on the clinical and commercial development of nivolumab which includes a product profile, clinical development program and timeline, SWOT, potential issues, strategy, etc. More details on the products contained in this briefing can be obtained upon special request.
Breast Cancer - Molecular Basis of HER2+ DiseaseFaryn
This presentation was part of a graduate level advanced molecular cell biology course. It reviews Breast Cancer epidemiology, signs 7 symptoms, diagnosis, genetic testing, hormonal testing and treatment options (briefly), then discusses the specifics of HER2+ cases at the cellular level. It shows how Herceptin and Tykerb work in the cell to block signal cascades, etc.
"Brief Introduction of China Food & Drug Administration" by Chang Yongheng, China Centre for Food and Drug International Exchange, China Food & Drug Administration
How can immunotherapy be used to treat metastatic breast cancer? Ian Krop, MD, PhD, discusses the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 and hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Tratamiento inicial de pacientes posmenopáusicas con cáncer de mama HR+/her2-...Mauricio Lema
Versión 2 (definitiva): Presentado en la Clínica VIDA en 11.11.2016, por invitación de Jairo Estrada. Versión corregida (se corrigen errores en 3 diapositivas de la versión anterior).
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Pharma Intelligence
In conjunction with a Key Opinion Leader, Dr. Peter Lee MD Chair, Department of Immuno-Oncology at City of Hope Comprehensive Cancer Center, CA, several Informa analysts discuss the major developments of the conference and key take-aways via a Webinar.
Watch our recording of Biomedtracker's Robert Jeng, Ph,D., Citeline's Allison Bruce, Scrip's Mary Jo Laffler, and Datamonitor Healthcare's Zachary McLellan as they download and debrief following the always-exciting ASCO weekend.
View and listen to the full webinar here https://www.youtube.com/watch?v=7yMsCb3R5X8
Your fast-pass to the news, insights, and storylines you need to know.
Watch the full webinar here http://ow.ly/4mOGmk
Hosted by Master of Ceremonies Ian Lloyd, senior director of Pharmaprojects and data integration, this webinar spotlights the blockbuster trends and rising stars of global R&D 2016 as seen in this year’s Annual Review.
During this presentation, Ian Lloyd & Scrip Managing Editor, Alex Shimmings cover:
>> Year-on-year growth
>> Clinical phases trends
>> Top companies and the shape of the industry
>> Mergers and acquisitions
>> Trending therapies, diseases, drug types and delivery routes
>> Mechanisms and drug targets
This webinar is the essential pharma R&D trend and forecast overview you need to be positioned for success in 2016.
Watch the full webinar here http://ow.ly/4mOGmk
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Tahoe eLab
This presentation has been peer-reviewed for fair and balanced evidence-based medicine.
Status of FDA devices used for the material being presented: NA/Non-Clinical
Status of off-label use of devices, drugs or other materials that constitute the subject of this presentation: Discuss off-label use of chemotherapy drugs for different cancers.
This is a briefing on the PD-1 and PD-L1 targeted agents. This briefing provides a summary of the agents in clinical development for the treatment of cancer. The briefing specifically focusses on the clinical and commercial development of nivolumab which includes a product profile, clinical development program and timeline, SWOT, potential issues, strategy, etc. More details on the products contained in this briefing can be obtained upon special request.
Breast Cancer - Molecular Basis of HER2+ DiseaseFaryn
This presentation was part of a graduate level advanced molecular cell biology course. It reviews Breast Cancer epidemiology, signs 7 symptoms, diagnosis, genetic testing, hormonal testing and treatment options (briefly), then discusses the specifics of HER2+ cases at the cellular level. It shows how Herceptin and Tykerb work in the cell to block signal cascades, etc.
"Brief Introduction of China Food & Drug Administration" by Chang Yongheng, China Centre for Food and Drug International Exchange, China Food & Drug Administration
An Introduction of Healthcare Market in ChinaZiqian WANG
A research on healthcare market in China covering topics including an introduction of Public Hospital System, Chinese Physicians' Work Condition and Salaries, as well as Continued Medical Education system.
Regulatory Highlights and Drug Development in ChinaMedpace
Regulatory Highlights and Drug Development in China was presented at the 5th China Clinical Trials Outsourcing Congress March 4-5, 2013 by Xiaoxiong (Jim) Wei, MD, PhD, Medical Director at Medpace.
Lantern Pharma is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost. RADR® identifies genetic signature patterns that underpin the identification of patients for whom Lantern's portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. This is the future of precision medicine and Lantern is at the forefront of AI driven transformation that will change the lives of cancer patients.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Colorectal Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And...frankmorgan27
The increasing occurrences of polyps and inflammatory bowel conditions like ulcerative colitis or Crohn’s disease are primarily propelling the colorectal cancer market.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Lantern Pharma is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost. RADR® identifies genetic signature patterns that underpin the identification of patients for whom Lantern's portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. This is the future of precision medicine and Lantern is at the forefront of AI driven transformation that will change the lives of cancer patients.
Lantern Pharma is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost. RADR® identifies genetic signature patterns that underpin the identification of patients for whom Lantern's portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. This is the future of precision medicine and Lantern is at the forefront of AI driven transformation that will change the lives of cancer patients.
Lantern Pharma is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost. RADR® identifies genetic signature patterns that underpin the identification of patients for whom Lantern's portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. This is the future of precision medicine and Lantern is at the forefront of AI driven transformation that will change the lives of cancer patients.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
A presentation on Pharmacovigilance System in United States.
We at PharmXL International Pvt. Ltd., offer wide range of services for pharma industry like Pharmacovigilance services, Clinical Trials services, Regulatory Affairs services, Medical writing services etc to comply with required regulatory obligations across major regions.
For details visit: www.PharmXL.com
Email us: contact@pharmxl.com
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Analysis On Global Drugs for Prostate Cancer Market Research, Demands & Produ...Pallavi Pawar
The global Drugs for Prostate Cancer market the target of analysis of the research report recently added to the expansive database in QYResearchReports.com. The extremely descriptive and insightful document chalks out a thorough and all-inclusive analytical perspective of the global Drugs for Prostate Cancer market, covering all key categories and their segments, along with the factors that have the potential of being influential on the market in the near future. The report thus presents a 360-degree analysis of the current state of the global Drugs for Prostate Cancer market to the reader.
The market has been excavated from a ground-up fashion, where rudimentary data and key, industry-specific definitions of the global Drugs for Prostate Cancer market’s elements are described in the overview. The report moves ahead to the complete analysis of global Drugs for Prostate Cancer market, sticking to aspects such as classifications, industry chain structure, applications, policies, industry overview, and recent developments.
Lantern Pharma is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost. RADR® identifies genetic signature patterns that underpin the identification of patients for whom Lantern's portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. This is the future of precision medicine and Lantern is at the forefront of AI driven transformation that will change the lives of cancer patients.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Peptide Based Cancer Therapeutics Market Size Worth $17.18 Billion By 2027 | ...OliviaThomas57
The global peptide based cancer therapeutics market size is expected to reach USD 17.18 billion by 2027 according to a new study by Polaris Market Research
Experts from Informa’s Medtrack, Trialtrove and Strategic Transactions teams presented a panel discussion at the recent T3 Conference in Orlando, Florida.
2. Pharma intelligence | informa2
“Our drug is more
effective than the
marketed Lynparza
and late stage
Rucaparib.”
3. Pharma intelligence | informa3
View analysis on your competitor’s data (BioMedTracker)
Rucaparib Phase II – ARIEL2 Top-Line Results
Lynparza – Phase II – Study 19 (Maintenance Study)
4. Pharma intelligence | informa4
See how you stack up against competitors (BioMedTracker)
Likelihood of Approvals
5. Pharma intelligence | informa5
Know your competitors’ plans (BioMedTracker)
Tesaro’s plans for Niraparib in ovarian cancer
Clovis’ plans for Rucaparib in ovarian cancer
6. Pharma intelligence | informa6
What are the advantages of PARP Inhibitors? (Datamonitor)
7. Pharma intelligence | informa7
How many US patients are inflicted with Ovarian Cancer?
(Datamonitor)
Datamonitor forecasts that the number of diagnosed
incident cases for Ovarian Cancer will grow from 23,260 in
2015 to 26,690 in 2028.
8. Pharma intelligence | informa8
What’s the Size of the Ovarian Market? (Datamonitor)
Datamonitor forecasts that sales of key Ovarian
drugs across the US, Japan and Five major EU
markets will grow from $171m in 2015 to $667m
in 2023.
9. Pharma intelligence | informa9
How Much Money will Lynparza (PARP) Make? (Datamonitor)
Lynparza is expected to hit $182m in sales globally
in 2023.
10. Pharma intelligence | informa10
Events Impacting the Ovarian Cancer Market (Datamonitor)
11. Pharma intelligence | informa11
How does my Drug Compare Clinically and Commercially?
(Datamonitor)
12. Pharma intelligence | informa12
What is the current Ph 3 trial landscape for relapsed Ovarian
cancer? (Citeline)
15. Pharma intelligence | informa15
Who are the top Investigators we can work with? (Citeline)
16. Pharma intelligence | informa16
How much can we license our Phase I drug for? (Medtrack)
Historically several Phase I oncology drugs
treating ovarian cancer were able to achieve
between $450m-$693m in total deal value.
17. Pharma intelligence | informa17
What Deal Value can I expect for a PARP Inhibitor? (Medtrack)
Notable PARP deals include Clovis’
agreement with Pfizer for PF1367338 and
Medivation’s agreement with BioMarin for
talazoparib (an astounding $410m upfront).
